Company: DMAAR
Filing Date: 2025-02-04
Form Type: 8-K
Source: 0001213900-25-010079
Chunk: 0

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-02-04
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01. Other Events.

As
previously disclosed on a Current Report on Form 8-K dated January 27, 2025, Drugs Made In America Acquisition Corp. (the “ Company”)
consummated its initial public offering (the “ IPO”) of 20,000,000 units (the “ Units”). Each Unit consists of
one ordinary share (“ Ordinary Share”) and one right to receive one-eighth (1/8) of one Ordinary Share upon the consummation
of an initial business combination. The Units were sold at a price of $10.00 per Unit, generating aggregate gross proceeds to the Company
of $200,000,000.

Simultaneously
with the closing of the IPO, the Company consummated a private placement (the “ Private Placement”) in which Drugs Made
In America Acquisition LLC, the Company’s sponsor, purchased 400,000 private units at a price of $10.00 per unit, for
$4,000,000, of which $1,100,000 has not yet been received and is accounted for as a subscription receivable in the attached balance sheet.

As
of January 29, 2025, a total of $201,000,000 of the net proceeds from the IPO and the Private Placement were deposited in a trust account
established for the benefit of the Company’s public shareholders.